Advanced search×

Aromatase inhibitors: prediction of response and nature of resistance.

William R WR Miller

Expert Opin Pharmacother 11(11):1873-87 (2010) PMID 20497094

Aromatase inhibitors (AIs) are recommended for and central to endocrine management of breast cancer patients. Response rates can be high, but resistance is a major obstacle. Optimal management therefore requires accurate prediction of response and an understanding of the nature by which resistance occurs. These are the subjects of this review.

DOI: 10.1517/14656566.2010.487863
Version: za2963e q8zac q8zb0 q8zc1 q8zd9 q8ze2 q8zfa q8zg0

Similar articles you may find interesting…

  1. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistan...
    William R WR Miller and Alexey A Larionov

    Breast Cancer Research (Online Edition) 12(4):R52 (2010) PMID 20646288

    Different dynamic patterns of expression of oestrogen-regulated and proliferation genes were observed in tumours clinically resistant to neoadjuvant letrozole, thus illustrating heterogeneity of resistance and discriminating molecular sub-classes of resistant tumours. Molecular phenotyping might hel...
    View PDF
  2. Left-handed DNA can be right
    Albert Erives

    Nature 467(7317):789 (2010)

  3. Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estroge...
    Selma S Masri, Sheryl S Phung, ... Shiuan S Chen

    Cancer Res 68(12):4910-8 (2008) PMID 18559539

    Acquired resistance to either tamoxifen or aromatase inhibitors (AI) develops after prolonged treatment in a majority of hormone-responsive breast cancers. In an attempt to further elucidate mechanisms of acquired resistance to AIs, MCF-7aro cells resistant to letrozole (T+LET R), anastrozole (T+ANA...